11,231 Shares in Nevro Corp. (NYSE:NVRO) Acquired by Virtu Financial LLC

Virtu Financial LLC bought a new stake in shares of Nevro Corp. (NYSE:NVRO) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,231 shares of the medical equipment provider’s stock, valued at approximately $63,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. ArrowMark Colorado Holdings LLC raised its stake in shares of Nevro by 2.4% in the third quarter. ArrowMark Colorado Holdings LLC now owns 4,391,258 shares of the medical equipment provider’s stock worth $24,547,000 after buying an additional 102,150 shares during the period. Armistice Capital LLC raised its stake in Nevro by 1.3% during the 2nd quarter. Armistice Capital LLC now owns 3,672,000 shares of the medical equipment provider’s stock worth $30,918,000 after acquiring an additional 48,000 shares during the period. Engaged Capital LLC raised its stake in Nevro by 29.5% during the 3rd quarter. Engaged Capital LLC now owns 2,442,956 shares of the medical equipment provider’s stock worth $13,656,000 after acquiring an additional 557,000 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Nevro by 130.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,000,000 shares of the medical equipment provider’s stock valued at $5,590,000 after purchasing an additional 566,462 shares in the last quarter. Finally, Western Standard LLC bought a new position in shares of Nevro in the third quarter worth approximately $5,473,000. 95.52% of the stock is owned by hedge funds and other institutional investors.

Nevro Price Performance

NVRO stock opened at $3.79 on Friday. Nevro Corp. has a 52 week low of $3.52 and a 52 week high of $22.52. The firm has a market capitalization of $142.02 million, a P/E ratio of -2.01 and a beta of 0.84. The company has a fifty day simple moving average of $4.66 and a two-hundred day simple moving average of $6.31. The company has a quick ratio of 3.76, a current ratio of 5.02 and a debt-to-equity ratio of 0.67.

Nevro (NYSE:NVRO) last released its quarterly earnings results on Monday, November 11th. The medical equipment provider reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.40. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. The company had revenue of $96.60 million during the quarter, compared to analyst estimates of $93.09 million. During the same quarter last year, the business posted ($0.65) earnings per share. The firm’s revenue was down 7.0% on a year-over-year basis. Analysts anticipate that Nevro Corp. will post -2.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Robert W. Baird raised their price objective on shares of Nevro from $5.00 to $6.00 and gave the company a “neutral” rating in a research report on Tuesday, November 12th. Royal Bank of Canada restated a “sector perform” rating and issued a $7.00 price objective on shares of Nevro in a research report on Tuesday, November 12th. StockNews.com raised Nevro from a “sell” rating to a “hold” rating in a research note on Tuesday, November 19th. Wells Fargo & Company lowered their price target on Nevro from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Finally, Canaccord Genuity Group cut their price objective on shares of Nevro from $7.00 to $4.00 and set a “hold” rating for the company in a report on Monday, December 9th. Three analysts have rated the stock with a sell rating and twelve have issued a hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $7.97.

Nevro Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.